Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Beleaguered oncology biotech Five Prime Therapeutics has been thrown a lifeline by Seattle Genetics, the antibody-drug conjugate (ADC) specialist, in the form of a global licensing agreement. 20 February 2020
Biotechnology
USA-based FORMA Therapeutics today announced the US Food and Drug Administration has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, FT-4202, in development as a disease-modifying treatment for sickle cell disease (SCD). 20 February 2020
Biotechnology
Belgian drugmaker UCB was trading more than 3% higher by lunchtime on Thursday after presenting its financial results for 2019. 20 February 2020
Biotechnology
US biotech major Gilead Sciences announced today that Michael Quigley has joined the company as senior vice president, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology. 19 February 2020
Biotechnology
Israeli company NeoTX, a biotech firm with a selective t-cell redirection (STR) platform for developing targeted anticancer immunotherapies, has closed a $45 million Series C financing. 19 February 2020
Biotechnology
Australian biotech firm Immutep today announced positive interim data from its ongoing Phase II TACTI-002 study, news of which pushed its share up 14.1% to A$0.44 by close of trading. 19 February 2020
Biotechnology
A second Phase III study from Incyte’s TRuE-AD clinical trial program in mild-to-moderate atopic dermatitis (AD) has met its primary endpoint. 19 February 2020
Biotechnology
Shares of biotech firm Cellectis were up more than 2% at 16.09 euros by early afternoon today, after it announced the execution of a binding term sheet with fellow France-based Servier to enter into an amendment to the agreement initially signed between the two companies in 2014. 19 February 2020
Biotechnology
The US Food and Drug Administration has awarded Priority Review status to a supplemental Biologics License Application for Tecentriq (atezolizumab) in non-small cell lung cancer (NSCLC). 19 February 2020
Biotechnology
Belgian bioprocessing provider Univercells has received an injection of 50 million euros from Gamma Biosciences, a new investment platform supported by private equity giant KKR that is focused on technologies for the production of advanced biologic therapies including gene and cell therapies. 19 February 2020
Biotechnology
Research from technology company RS Components shows that the global biotechnology market is expected to reach $727 billion by 2025. 19 February 2020
Biotechnology
Sanofi Pasteur revealed today it plans to leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a novel coronavirus (COVID-19) vaccine. 18 February 2020
Biotechnology
Government-funded non-profit CARB-X has taken a punt on another company that could help to tackle the emerging antimicrobial resistance crisis. 18 February 2020
Biotechnology
Independent drugmaker Servier and fellow France-based biotech Oncodesign (Euronext: ALONC) late Monday announced reaching an important milestone in their strategic partnership on potential drug candidates for Parkinson’s disease, news of which sent Oncodesign’s shares leaping 17% to 11.70 euros in early trading this morning. 18 February 2020
Biotechnology
The first patients in England have been treated with Novartis’ Luxturna (voretigene neparvovec), after the company reached a reimbursement deal in the UK in late 2019. 18 February 2020
Biotechnology
Ahmedabad-based Zydus Cadila, a part of Cadila Healthcare, has launched an accelerated research program to develop a vaccine for the novel coronavirus, COVID-19. 17 February 2020
Biotechnology
As has been widely expected following a positive advisory panel recommendation last December, the European Commission (EC) has now granted approval for Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). 17 February 2020
Biotechnology
Shares of UK-based ReNeuron Group rose as much as 4% in early trading, as the company announced the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase IIa clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke. 17 February 2020
Biotechnology
The Chinese Communist Party has said that biotech companies located at the heart of the coronavirus outbreak can now return to work, reports GlobalData. 14 February 2020
Biotechnology
Japanese drug major Chugai today said that polatuzumab vedotin in combination with bendamustine and rituximab (hereafter, BR therapy) had achieved the primary endpoint of complete response rate (CRR) by PET-CT at the timing of Primary Response Assessment (PRA) in the Japanese Phase II study (JO40762/P-DRIVE study). 14 February 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze